title: Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma.
abstract: Multiple myeloma (MM) plasma cells are apoptosis resistant. The system of Fas with its ligand (Fas-L) participates actively in the extrinsic apoptotic system. In oncology, its role is controversial, since it has been reported both to suppress and promote tumor growth. The aim of this study was to measure serum levels of soluble Fas-L (sFas-L) in patients with active MM and to correlate them with markers of disease activity. We studied 57 patients with active MM, along with 22 healthy controls. We measured serum levels of sFas-L and interleukin-6 (IL-6) by enzyme-linked immunosorbent assays, as well of beta-2 microglobulin (B2M), C-reactive protein (CRP) and lactate dehydrogenase (LDH). We also measured the degree of bone marrow infiltration. All parameters were increased in patients, compared with controls (p < 0.001 for all cases) and also in parallel with disease stage (p < 0.001 for all cases). Positive correlations were noted between serum levels of sFas-L with IL-6, infiltration (p < 0.001 for both cases) and LDH (p < 0.04), but not with CRP and B2M. We suggest that the system of Fas/Fas-L participates actively in MM progression in a complex manner and that serum levels of sFas-L may reflect disease progression. Further studies are needed to determine its usefulness as a marker of disease activity.
authors.affiliation: Hematology Department, University Hospital of Heraklion, PO Box 1352, 71110, Heraklion, Crete, Greece, alexandm@med.uoc.gr.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Alexandrakis
authors.forename: Constantina A
authors.initials: CA
authors.lastname: Pappa
authors.forename: Anna
authors.initials: A
authors.lastname: Kolovou
authors.forename: Stavroula
authors.initials: S
authors.lastname: Kyriakaki
authors.forename: Rodanthi
authors.initials: R
authors.lastname: Vyzoukaki
authors.forename: Maria
authors.initials: M
authors.lastname: Devetzoglou
authors.forename: George
authors.initials: G
authors.lastname: Tsirakis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D015415:Biomarkers; D053222:Fas Ligand Protein
references.citation: Science. 1994 Jul 22;265(5171):528-30
references.pmid: 7518614
references.citation: J Exp Med. 1995 Dec 1;182(6):1777-83
references.pmid: 7500022
references.citation: Nature. 2009 Oct 1;461(7264):659-63
references.pmid: 19794494
references.citation: Arch Biochem Biophys. 2002 Dec 15;408(2):155-61
references.pmid: 12464266
references.citation: Leuk Lymphoma. 2008 Oct;49(10):1945-53
references.pmid: 18728964
references.citation: Oncogene. 2002 Aug 22;21(37):5673-83
references.pmid: 12173037
references.citation: Leuk Lymphoma. 2006 Feb;47(2):271-80
references.pmid: 16321857
references.citation: Int J Cancer. 2000 Mar 20;89(2):127-32
references.pmid: 10754489
references.citation: Br J Haematol. 1996 Aug;94(2):379-82
references.pmid: 8759901
references.citation: Nature. 2010 May 27;465(7297):492-6
references.pmid: 20505730
references.citation: J Biol Chem. 2012 Jul 20;287(30):25530-40
references.pmid: 22669972
references.citation: Gynecol Oncol. 2003 Jul;90(1):70-4
references.pmid: 12821344
references.citation: J Mol Med (Berl). 2000;78(6):312-25
references.pmid: 11001528
references.citation: J Immunol. 2010 Sep 1;185(5):2721-9
references.pmid: 20660713
references.citation: Gut. 2005 May;54(5):661-5
references.pmid: 15831912
references.citation: J Immunol. 2003 Sep 1;171(5):2402-12
references.pmid: 12928387
references.citation: J Exp Med. 1998 Apr 20;187(8):1205-13
references.pmid: 9547332
references.citation: Int J Oncol. 2001 Jun;18(6):1157-62
references.pmid: 11351245
references.citation: Cancer. 2000 Feb 1;88(3):524-8
references.pmid: 10649242
references.citation: Mol Cell Biol. 2003 Feb;23(4):1428-40
references.pmid: 12556501
references.citation: Cell Immunol. 1995 May;162(2):248-55
references.pmid: 7743552
references.citation: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2205-9
references.pmid: 9815616
references.citation: Am J Clin Pathol. 2005 Jun;123(6):879-85
references.pmid: 15899779
references.citation: PLoS One. 2010 Feb 05;5(2):e9070
references.pmid: 20140201
references.citation: Science. 1995 Mar 10;267(5203):1449-56
references.pmid: 7533326
references.citation: Toxicol Pathol. 2007 Jun;35(4):495-516
references.pmid: 17562483
references.citation: Leuk Lymphoma. 2001 Jan;40(3-4):351-6
references.pmid: 11426557
references.citation: Recent Results Cancer Res. 2011;183:39-86
references.pmid: 21509680
references.citation: Lab Invest. 2001 Feb;81(2):177-84
references.pmid: 11232639
references.citation: Curr Med Chem. 2008;15(17):1684-96
references.pmid: 18673218
references.citation: J Rheumatol. 2001 Jan;28(1):22-8
references.pmid: 11196534
references.citation: Nat Med. 1996 Mar;2(3):317-22
references.pmid: 8612231